ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
82.79
+0.41 (+0.50%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close82.38
Open82.41
Bid81.72 x 800
Ask83.49 x 900
Day's Range82.03 - 83.32
52 Week Range65.44 - 88.76
Volume4,846,096
Avg. Volume4,529,292
Market Cap146.323B
Beta (3Y Monthly)0.80
PE Ratio (TTM)50.92
EPS (TTM)1.63
Earnings DateOct 16, 2019
Forward Dividend & Yield1.28 (1.57%)
Ex-Dividend Date2019-07-12
1y Target Est94.03
Trade prices are not sourced from all markets
  • 3 Medical Product Stocks Likely to Beat This Earnings Season
    Zacks

    3 Medical Product Stocks Likely to Beat This Earnings Season

    Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

  • Thomson Reuters StreetEvents

    Edited Transcript of ABT earnings conference call or presentation 16-Oct-19 1:00pm GMT

    Q3 2019 Abbott Laboratories Earnings Call

  • Investors Shrug Off Abbott's Mixed Report; Stock Bounces Off 200-Day Line
    Investor's Business Daily

    Investors Shrug Off Abbott's Mixed Report; Stock Bounces Off 200-Day Line

    Abbott earnings of 84 cents per share met expectations in the third quarter, but $8.08 billion in sales was just light of estimates. Abbott stock rose slipped a fraction on Wednesday.

  • How Abbott Stock Reacted to the Company’s Q3 Results
    Market Realist

    How Abbott Stock Reacted to the Company’s Q3 Results

    Healthcare giant Abbott Laboratories announced its third-quarter earnings results before markets opened today. Its stock was trading at $83.66 midday.

  • T Rowe Price Equity Income Fund's Top 5 Buys in the 3rd Quarter
    GuruFocus.com

    T Rowe Price Equity Income Fund's Top 5 Buys in the 3rd Quarter

    Fund establishes two new holdings and boosts GE stake Continue reading...

  • 5 Top Stock Trades for Thursday: ADBE, NFLX, ABT
    InvestorPlace

    5 Top Stock Trades for Thursday: ADBE, NFLX, ABT

    The indices did not move too much on Wednesday, but a handful of tech stocks were hit hard on the day. Let's look at a few of the top stock trades going into the latter half of the week. Top Stock Trades for Tomorrow No. 1: Adobe (ADBE)Adobe Systems (NASDAQ:ADBE) came under pressure Wednesday following a downgrade from Citi analysts.InvestorPlace - Stock Market News, Stock Advice & Trading TipsShares have been trying to break out over downtrend resistance (blue line) and were actually succeeding before Wednesday. However, the tepid bullish action was not enough to withstand today's selling.Nor were the 20-day and 200-day moving averages, as ADBE stock gapped below both metrics. However, it's finding some reprieve from the 38.2% retracement. Now investors want to know, can ADBE reclaim the 200-day and downtrend resistance or are lower prices in store?If it's the latter, look for a decline down into the $258 to $260 area. There it will find a notable level of support as well as the 50% retracement. If that fails to hold, ADBE stock may be in trouble. On the upside, the charts are pretty cluttered until Adobe can clear the 50-day moving average. Top Stock Trades for Tomorrow No. 2: Netflix (NFLX)Netflix (NASDAQ:NFLX) is very much a mixed picture ahead of the company's earnings report on Wednesday after the close.On the plus side, shares have broken out over downtrend resistance (blue line) and are maintaining above the 20-day moving average. On the downside, they are stuck below the 50-day moving average and the 38.2% retracement.So what now?Should shares decline, look to see if the 23.6% retracement at $267.75 can support the name. If not, $260 could be on deck, with the September low of $252.28 below that. Below the September low and the December low is possible.On the upside, see that NFLX reclaims and holds the 50-day moving average and 38.2% retracement. Above that opens the door to the 50% and 61.8% retracements at $308.61 and $326.81, respectively. Top Stock Trades for Tomorrow No. 3: Abbott Labs (ABT)Abbott Labs (NYSE:ABT) was mixed on Wednesday after it reported earnings. However, with clear-cut support nearby and breakout potential, it's worth watching.Look at the past year of action. Shares have a consolidation period, then tend to break out to new highs and consolidate again. The old highs also tend to become support.Luckily, the prior highs near $79 to $80 also intersect with the 200-day moving average and 61.8% retracement. That makes it a pretty solid risk/reward area for investors. Below $79 and traders may consider stopping out.On the upside, see if ABT stock can break out over downtrend resistance and the 50-day moving average. Over it and a move back to $86-plus could be in the cards. Top Stock Trades for Tomorrow No. 4: ServiceNow (NOW)ServiceNow (NYSE:NOW) was hammered on Wednesday and it leaves the stock clinging to support. Shares are just above the 200-day moving average and range support near $250.Below $250 and the October low of $243.54 is on the table. Below that and the stock could struggle a bit.If support holds, look for NOW to reclaim the 50-day moving average and rally back up to range resistance near $275. Over $275 and perhaps ServiceNow could retest the backside of its prior uptrend (blue line). Top Stock Trades for Tomorrow No. 5: Workday (WDAY)Thought ServiceNow investors were having a bad day? Just look at Workday (NASDAQ:WDAY), which was hit even harder on the day.The 61.8% retracement held WDAY in check on Tuesday, and on Wednesday the 38.2% retracement is acting as bulls' saving grace. Below the 38.2% and Wednesday's low, and the $145 mark could be on the table.If current support at the 38.2% retracement holds, look for WDAY to reclaim the $165 to $166 area. Above that and it will also have to reclaim downtrend resistance.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks to Buy (With Brands You Can Find In Your Kitchen) * 7 Hot & Trendy Generation Z Stocks to Buy * 5 Stocks to Buy in the Mighty Middle The post 5 Top Stock Trades for Thursday: ADBE, NFLX, ABT appeared first on InvestorPlace.

  • Abbott Labs, GM, MGM, Berkshire Hathaway, Intel: Stocks to Watch
    Yahoo Finance

    Abbott Labs, GM, MGM, Berkshire Hathaway, Intel: Stocks to Watch

    Abbott Labs, GM, MGM, Berkshire Hathaway and Intel are the companies to watch.

  • Abbott (ABT) Meets Q3 Earnings Estimates, Lowers EPS Guidance
    Zacks

    Abbott (ABT) Meets Q3 Earnings Estimates, Lowers EPS Guidance

    We are optimistic about Abbott's (ABT) strong and consistent EPD and Medical Devices performance organically.

  • Benzinga

    Abbott Laboratories Reports Mixed Q3 Earnings

    Abbott Laboratories (NYSE: ABT ) reported third-quarter earnings of 84 cents per share, which met the analyst consensus estimate. This is a 12% increase over earnings of 75 cents per share from the same ...

  • Abbott revenue misses as heart devices eclipse diabetes gains
    Reuters

    Abbott revenue misses as heart devices eclipse diabetes gains

    A 63% jump in sales of FreeStyle Libre continuous glucose monitor powered the diabetes unit's better-than-expected revenue of $665 million. The device helps diabetics track blood sugar levels without having to prick their fingers, and the company is awaiting the Food and Drug Administration's approval for the next-generation version of the device, the Freestyle Libre 2.0.

  • MarketWatch

    Abbott Labs stock falls after profit matches expectations, sales comes up a bit shy

    Shares of Abbott Laboratories fell 2.7% in premarket trading Wednesday, after medical device, diagnostics and drug maker reported a third-quarter profit that was in line with expectations, while sales came up a bit shy. Net income rose to $960 million, or 53 cents a share, from $563 million, or 32 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew to 84 cents from 75 cents, matching the FactSet consensus of 84 cents. Sales increased 5.5% to $8.08 billion, below the FactSet consensus of $8.11 billion. Within Abbott's business segments, revenue for medical devices was slightly above expectations, while nutrition, diagnostics and established pharmaceuticals was slightly below. Looking ahead, Abbott expects fourth-quarter adjusted EPS of 94 cents to 96 cents, surrounding the FactSet consensus of 95 cents, and narrowed its 2019 guidance range to $3.23 to $3.25 from $3.21 to $3.27. The stock has gained 13.3% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has advanced 5.8% and the S&P 500 has climbed 19.5%.

  • PR Newswire

    Abbott Reports Third-Quarter 2019 Results

    - Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent - Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity - Continues to strengthen portfolio ...

  • ACCESSWIRE

    Abbott Laboratories to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / October 16, 2019 / Abbott Laboratories (NYSE: ABT ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 16, 2019 at 9:00 AM ...

  • TheStreet.com

    [video]Stocks End Down as Trade War Fears, Weak Retail Sales Overshadow Strong Earnings

    Stocks finish down as investors divide their attention between strong third-quarter earnings and concerns over weak U.S. retail sales and the ongoing U.S.-China trade war.

  • TheStreet.com

    Abbott Laboratories Narrows 2019 Profit Guidance After In-Line Q3 Earnings

    Abbott Laboratories posted third quarter earnings that were largely in-line with Wall Street forecasts Wednesday, but narrowed its full-year profit forecast.

  • Investing.com

    Abbott Labs Earnings inline, Revenue Misses In Q3

    Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that matched analysts' expectations on Wednesday and revenue that fell short of forecasts.

  • Abbott Partnership Helps One Medtech Stock To Pop — As Another Dives
    Investor's Business Daily

    Abbott Partnership Helps One Medtech Stock To Pop — As Another Dives

    Tandem Diabetes stock popped Tuesday on a partnership deal with medical behemoth Abbott Laboratories in diabetes treatment. The medical technology firms will integrate their medical devices.

  • Options Red-Hot Ahead of Abbott Earnings
    Schaeffer's Investment Research

    Options Red-Hot Ahead of Abbott Earnings

    Abbott Laboratories just announced a $3 billion buyback plan

  • Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
    Zacks

    Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?

    Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.

  • Abbott Labs Rises 3%
    Investing.com

    Abbott Labs Rises 3%

    Investing.com - Abbott Labs (NYSE:ABT) rose by 3.02% to trade at $82.23 by 13:50 (17:50 GMT) on Tuesday on the NYSE exchange.

  • Abbott Forms Alliance With Omada Health for Diabetes Care
    Zacks

    Abbott Forms Alliance With Omada Health for Diabetes Care

    Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.

  • MarketWatch

    Abbott Labs gets authorization for $3 billion in additional buybacks

    Abbott Laboratories Inc. said in a Tuesday filing that its board had authorized an additional $3 billion in share repurchases. The company said there is still a $795 million unused portion of its prior buyback program, which received approval in September 2014. Also on Tuesday, Abbott Labs announced that it would partner with Tandem Diabetes Care on diabetes-management options. Abbott Labs shares are up 0.9% in premarket trading Tuesday. The stock has risen 10% so far this year, as the S&P 500 has gained 18%.

  • TheStreet.com

    DexCom Falls After Rival Tandem Teams With Abbott for Insulin Pump

    DexCom shares fell Tuesday after rival Tandem Diabetes Care said it was partnering with Abbott Labs to develop a new insulin pump featuring Abbott's glucose-sensing technology. Tandem and Abbott "can provide new ways for people to manage their diabetes" that "can integrate easily into their daily lives, especially people who rely on insulin pumps," Abbott Vice President Jared Watkin said in a statement. The partnership ends exclusivity for DexCom in the space and exposes 15% of the company's sales to competition, according to Bloomberg.

  • PR Newswire

    Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management

    - Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes ABBOTT PARK, Ill. and SAN DIEGO , Oct. ...

  • Abbott Labs, GM, MGM, Berkshire Hathaway, Intel: Companies to Watch
    Yahoo Finance Video

    Abbott Labs, GM, MGM, Berkshire Hathaway, Intel: Companies to Watch

    Abbott Labs, GM, MGM, Berkshire Hathaway and Intel are the companies to watch.